Serum TNF-α in psoriasis after treatment with propylthiouracil, an antithyroid thioureylene

BMC Dermatology

Volumn 4, Issue , 2004, Pages

  Elias, Alan N ^a   Nanda, Vanda S ^b   Pandian, Raj ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; PROPYLTHIOURACIL; SULFONAMIDE; THIOUREA DERIVATIVE; THIOUREYLENE; THYROTROPIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIMETABOLITE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HYPOTHYROIDISM; LEUKOCYTE COUNT; LONG TERM CARE; MALE; PROTEIN BLOOD LEVEL; PSORIASIS VULGARIS; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; BLOOD; CLINICAL TRIAL; MIDDLE AGED; PSORIASIS;

ADULT; AGED; ANTIMETABOLITES; ANTITHYROID AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPYLTHIOURACIL; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10444240964     PISSN: 14715945     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-5945-4-4     Document Type: Article

References (30)

1. Linden KG, Weinstein GD: Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999, 107:595-605.
2. Greaves MW, Weinstein GD: Treatment of psoriasis. N Engl J Med 1995, 332:581-588.
3. Krueger GG, Duvic M: Epidemiology of psoriasis: clinical issues. J Invest Dermatol 1994, 102:14S-18S.
4. Bowcock AM, Barker JN: Genetics of psoriasis: the potential impact on new therapies. J Am Acad Dermatol 2003, 49:S51-56.
5. Barker JN: The pathophysiology of psoriasis. Lancet 1991, 338:227-230.
6. Nickoloff BJ, Schroder JM, von den Driesch P, Raychaudhuri SP, Farber EM, Boehncke WH, Morhenn VB, Rosenberg EW, Schon MP, Holick MF: Is psoriasis a T-cell disease? Exp Dermatol 2000, 9: 59-375.
7. Nickoloff BJ, Wrone-Smith T: Superantigens, autoantigens, and pathogenic T cells in psoriasis. J Invest Dermatol 1998, 110:459-460.
8. England RJ, Strachan DR, Knight LC: Streptococcal tonsillitis and its association with psoriasis: a review. Clin Otolaryngol 1997, 22:532-535.
9. Skov L, Baadsgaard O: Bacterial superantigens and inflammatory skin diseases. Clin Exp Dermatol 2000, 25: 7-61.
10. Nickoloff BJ: Creation of psoriatic plaques: the ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease. Viewpoint. J Cutan Pathol 2001, 28:57-64.
11. Nickoloff BJ: The immunologic and genetic basis of psoriasis. Arch Dermatol 1999, 135:1104-1110.
12. Asadullah K, Docke WD, Volk HD, Sterry W: The pathophysiological role of cytokines in psoriasis. Drugs Today (Barc.) 1999, 35:913-924.
13. Wrone-Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP, Nickoloff BJ: Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997, 151:1321-1329.
14. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D, D'Auria L, Fazio M, Ameglio F: Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997, 11: 15-118.
15. Bonifati C, Carducci M, Cordiali Fei P, Trento E, Sacerdoti G, Fazio M, Ameglio F: Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 1994, 19:383-387.
16. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994, 96:146-151.
17. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG: Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003, 48: 29-835.
18. Chaudhari UP, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001, 357: 842-1847.
19. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003, 349:2014-2022.
20. Elias AN, Barr RJ: Low-dose oral propylthiouracil in the treatment of plaque psoriasis. Int J Dermatol 1995, 34: 19-520.
21. Elias AN, Goodman MM, Liem WH, Barr RJ: Propylthiouracil in psoriasis: results of an open trial. J Am Acad Dermatol 1993, 29:78-81.
22. Elias AN, Goodman MM, Rohan MK, Alpern K, Barr RJ: Methimazole (2-mercapto 1-methyl imidazole) in psoriasis - results of an open trial. Dermatology 1993, 187:26-29.
23. Kose K, Utas S, Yazici C, Akdas A, Kelestimur F: Effect of propylthiouracil on adenosine deaminase activity and thyroid function in patients with psoriasis. Br J Dermatol 2001, 144: 121-1126.
24. Utas S, Kose K, Yazici C, Akdas A, Kelestimur F: Antioxidant potential of propylthiouracil in patients with psoriasis. Clin Biochem 2002, 35:241-246.
25. Elias AN, Barr RJ, Rohan MK, Dangaran K: Effect of orally administered antithyroid thioureylenes on PCNA and P53 expression in psoriatic lesions. Int J Dermatol 1995, 34:280-283.
26. Baadsgaard O, Fisher G, Voorhees JJ, Cooper KD: The role of the immune system in the pathogenesis of psoriasis. J Invest Dermatol 1990, 95:32S-34S.
27. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993, 101:701-705.
28. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003, 290:3073-3080.
29. Elias AN, Goodman MM, Rohan MK: Serum ICAM-1 concentrations in patients with psoriasis treated with antithyroid thioureylenes. Clin Exp Dermatol 1993, 18:526-529.
30. Elias AN, Nanda VS, Barr RJ: Effect of PTU on IL-12 and IL-10 in psoriasis. J Drugs Dermatol 2003, 2:645-648.